Reagents Required for Newborn Screening assay. – Qiagen LLC

This is a single source posting notification; there are no solicitation documents for download. Note this posting is not a Request for Bid (RFB) or Request for Proposal (RFP).

The Minnesota Department of Health (MDH) intends to enter a onetime agreement with Qiagen LLC to purchase Generation DNA Purification Solution and Generation DNA Elution Solution. These reagents are required for the Newborn Screening (NBS) lab’s assay for Severe Combined Immunodeficiency (SCID), Spinal Muscular Atrophy (SMA), and to validate a new addition to the Newborn Screening testing panel Congenital Cytomegalovirus (CMV). This assay uses the extraction method for our Cystic Fibrosis (CF) test, which has been previously validated. These are the only validated reagents that can be used, and they are only available from Qiagen.

This has been deemed a single source, as the purification and elution solutions are only available from Qiagen. These are the only reagents that work with the currently validated CF method and SMA and SCID assays and are needed to validate CMV assay. Different reagents would require a new method validation and would not be compatible with all three assays which have different requirements for the DNA extraction.

If there are any concerns regarding this single source o pportunity, contact Maria Rodriguez at Maria.rodriguez@state.mn.us by February 6, 2025, at 2:00 PM Central Time. Include the reference number and title of the posting in the subject line.